The Opioid REMS And Pharma’s Reputation: Slow Uptake May Become Significant Vulnerability
This article was originally published in RPM Report
Executive Summary
The ongoing review of the best regulatory strategies to limit harm from opioid pain therapies raises some dangerous themes at a difficult time for the biopharmaceutical industry.